FDA Approves LEUPROLIDE ACETATE — Sun Pharmaceutical Industries, Inc.

# FDA Approves Sun Pharmaceutical's Generic Leuprolide Acetate Sun Pharmaceutical Industries, Inc. received FDA approval for its generic leuprolide acetate formulation on March 9, 2009, marking a significant entry into the hormone therapy market and enabling the company to capture market share from branded competitors. The approval allows Sun Pharma to offer a more cost-effective alternative for patients requiring leuprolide treatment for conditions such as prostate cancer and endometriosis, potentially driving substantial revenue growth in the generic oncology and specialty pharmaceutical segments.